Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-3.97 Insider Own3.90% Shs Outstand42.15M Perf Week-7.37%
Market Cap222.55M Forward P/E- EPS next Y-2.42 Insider Trans-27.22% Shs Float38.30M Perf Month-4.35%
Income-140.10M PEG- EPS next Q-0.73 Inst Own92.90% Short Float7.89% Perf Quarter-23.48%
Sales14.00M P/S15.90 EPS this Y-61.10% Inst Trans-3.36% Short Ratio5.39 Perf Half Y-42.04%
Book/sh4.42 P/B1.19 EPS next Y15.10% ROA-61.80% Target Price25.17 Perf Year-73.12%
Cash/sh3.25 P/C1.63 EPS next 5Y- ROE-78.00% 52W Range5.04 - 21.97 Perf YTD-28.55%
Dividend- P/FCF- EPS past 5Y- ROI-55.10% 52W High-75.97% Beta1.26
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin38.20% 52W Low4.76% ATR0.40
Employees169 Current Ratio4.30 Sales Q/Q354.50% Oper. Margin- RSI (14)35.84 Volatility4.98% 7.17%
OptionableYes Debt/Eq0.17 EPS Q/Q7.00% Profit Margin- Rel Volume0.65 Prev Close5.64
ShortableYes LT Debt/Eq0.16 EarningsMay 08 AMC Payout- Avg Volume561.09K Price5.28
Recom1.30 SMA20-15.14% SMA50-13.85% SMA200-45.17% Volume361,974 Change-6.38%
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
May-17-19 09:05AM  Rigel Initiates Enrollment in Pivotal Blood Disorder Study Zacks
May-16-19 01:09PM  Aclaris Therapeutics, Inc. (ACRS) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 12:05AM  Edited Transcript of ACRS earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents -9.82%
May-08-19 06:55PM  Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:46PM  Aclaris: 1Q Earnings Snapshot Associated Press
04:01PM  Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
May-07-19 03:03PM  How Do Analysts See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Performing In The Years Ahead? Simply Wall St.
May-01-19 07:00AM  Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-25-19 07:00AM  Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis GlobeNewswire +6.89%
Apr-24-19 07:00AM  Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata GlobeNewswire
Apr-05-19 03:04PM  Consider These 3 Falling Knives GuruFocus.com
Apr-03-19 10:47AM  Edited Transcript of ACRS earnings conference call or presentation 18-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-27-19 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conference GlobeNewswire
Mar-18-19 01:15PM  Aclaris Therapeutics, Inc. (ACRS) Q4 2018 Earnings Conference Call Transcript Motley Fool +20.43%
07:34AM  Aclaris: 4Q Earnings Snapshot Associated Press
07:00AM  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
06:00AM  Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-19 04:01PM  Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019 GlobeNewswire
Feb-28-19 07:00AM  Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg GlobeNewswire
Feb-19-19 07:00AM  Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology GlobeNewswire -7.01%
Jan-18-19 12:30PM  Should You Worry About Aclaris Therapeutics, Inc.s (NASDAQ:ACRS) CEO Salary Level? Simply Wall St.
Jan-02-19 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Dec-23-18 03:52AM  Do Hedge Funds Love Aclaris Therapeutics, Inc. (ACRS)? Insider Monkey
Dec-21-18 07:27AM  Aclaris Therapeutics Enters Oversold Territory Zacks
Dec-18-18 07:00AM  Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada CNW Group -10.00%
Dec-17-18 04:01PM  Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials GlobeNewswire
Dec-11-18 03:17PM  Top 6 Performing IPOs of 2015 (ONCE, GBT) Investopedia
Dec-03-18 07:00AM  Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan GlobeNewswire
Nov-28-18 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Nov-27-18 08:31AM  Aclaris Therapeutics (ACRS) Enters Oversold Territory Zacks
07:50AM  Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-18-18 11:51PM  Edited Transcript of ACRS earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-06-18 06:05PM  Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:01PM  Aclaris: 3Q Earnings Snapshot Associated Press
04:01PM  Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
Nov-02-18 04:01PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Oct-30-18 10:33AM  Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-18 04:01PM  Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire
Oct-23-18 01:27PM  One Thing To Remember About The Aclaris Therapeutics Inc (NASDAQ:ACRS) Share Price Simply Wall St.
Oct-22-18 04:01PM  Aclaris Announces Closing of Public Offering of Common Stock GlobeNewswire
Oct-19-18 12:53PM  Aclaris plans $92.9M public stock offering American City Business Journals
Oct-17-18 09:44PM  Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire
08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
Oct-16-18 07:27PM  Edited Transcript of ACRS earnings conference call or presentation 15-Oct-18 9:00pm GMT Thomson Reuters StreetEvents -7.08%
11:52AM  $65 million deal: Aclaris buying rights to rosacea drug from Allergan American City Business Journals
Oct-15-18 04:01PM  Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan GlobeNewswire
Oct-10-18 02:42PM  Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-03-18 07:00AM  Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference GlobeNewswire
Oct-02-18 07:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-01-18 04:01PM  Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA® (hydrogen peroxide) Topical Solution 40%, (w/w) GlobeNewswire
01:25PM  Aclaris partnership with St. Louis university targets aspiring scientists from underrepresented minority groups American City Business Journals
07:00AM  Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups GlobeNewswire
Sep-24-18 07:00AM  Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts GlobeNewswire
Sep-21-18 07:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Sep-17-18 07:00AM  Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting GlobeNewswire
Sep-05-18 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-21-18 07:00AM  Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research GlobeNewswire
Aug-16-18 07:40AM  Edited Transcript of ACRS earnings conference call or presentation 3-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-03-18 09:25AM  Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:15AM  Aclaris: 2Q Earnings Snapshot Associated Press
07:00AM  Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
06:00AM  Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 07:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-31-18 08:25AM  Recent Analysis Shows Solar Capital, Aclaris Therapeutics, Fidus Investment, NetApp, RLJ Lodging Trust, and AvalonBay Communities Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-26-18 07:00AM  Aclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018 GlobeNewswire -5.94%
Jul-10-18 09:58AM  Aclaris' Alopecia Candidate Gets Fast Track Designation Zacks
Jul-09-18 07:00AM  FDA grants Fast Track Designation to Aclaris Therapeutics Investigational JAK Inhibitor for the treatment of Alopecia Areata GlobeNewswire
Jul-06-18 10:34AM  Aclaris Stock Up on JAK Inhibitor's Encouraging Activity Zacks
Jul-03-18 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-28-18 04:30PM  Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata GlobeNewswire
Jun-26-18 07:00AM  Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis GlobeNewswire
Jun-15-18 07:00AM  Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer GlobeNewswire
Jun-12-18 07:00AM  Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA is safe and effective in treating persons with raised seborrheic keratoses GlobeNewswire
Jun-04-18 04:05PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-01-18 07:40AM  Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018 ACCESSWIRE
May-30-18 07:00AM  Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA GlobeNewswire -5.54%
May-24-18 04:05PM  Landec Corporation to Nominate Two New Board Directors GlobeNewswire
May-19-18 04:10PM  Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching Benzinga
May-16-18 07:00AM  Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting GlobeNewswire
May-15-18 04:01PM  Edited Transcript of ACRS earnings conference call or presentation 8-May-18 9:00pm GMT Thomson Reuters StreetEvents
07:00AM  Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting GlobeNewswire
May-11-18 07:00AM  Aclaris Therapeutics to Present at the 2018 American Hair Research Summit GlobeNewswire
May-10-18 05:00PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
May-08-18 05:52PM  Aclaris: 1Q Earnings Snapshot Associated Press
04:01PM  Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
12:27PM  Aclaris Therapeutics Inc (NASDAQ:ACRS): Immense Growth Potential? Simply Wall St.
May-07-18 10:00AM  Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) GlobeNewswire
May-02-18 07:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-24-18 04:05PM  Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
04:05PM  Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee GlobeNewswire
Apr-23-18 07:00AM  Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia GlobeNewswire
Apr-18-18 07:35AM  Investor Expectations to Drive Momentum within Casella Waste, Prologis, Flushing Financial, AMERISAFE, Aclaris Therapeutics, and NanoString Technologies Discovering Underlying Factors of Influence GlobeNewswire
Apr-06-18 07:00AM  Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics CNW Group
07:00AM  Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada GlobeNewswire
Apr-03-18 04:05PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-29-18 08:10AM  Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-21-18 07:30AM  Blog Exposure - Aclaris Therapeutics Shares Positive Update on Phase-2 Results after a 3-Month Follow-Up of A-101 45% Topical Solution ACCESSWIRE
Mar-20-18 07:00AM  Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine GlobeNewswire
Mar-19-18 08:00AM  Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts GlobeNewswire
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James E10% OwnerMay 10Sale6.05180,5651,092,2741,166,959May 13 05:24 PM
Flynn James E10% OwnerMay 09Sale6.16434,1452,673,2481,238,828May 13 05:24 PM
Mehra AnandDirectorOct 22Buy10.75372,0934,000,0001,911,573Oct 23 07:13 PM
Tullman Stephen A.DirectorOct 04Buy14.007,10099,370177,457Oct 05 04:37 PM
Tullman Stephen A.DirectorAug 23Buy15.006,60098,985170,357Aug 27 04:46 PM
Tullman Stephen A.DirectorAug 15Buy15.976,25099,813163,757Aug 17 04:55 PM
Ali-Jackson KamilChief Legal OfficerJun 12Sale20.004,90098,00077,636Jun 12 06:42 PM
Ali-Jackson KamilChief Legal OfficerJun 11Sale20.001002,00082,536Jun 12 06:42 PM
open in yahoo | open in reuters | open in google